Skip to Content
Merck
All Photos(2)

Documents

MAB4133

Sigma-Aldrich

Anti-p16 Antibody, clone D25

clone D25, Chemicon®, from mouse

Synonym(s):

INK4a, MTS1, CDK4IN, CDKN2

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

purified antibody

antibody product type

primary antibodies

clone

D25, monoclonal

species reactivity

human

manufacturer/tradename

Chemicon®

technique(s)

immunohistochemistry: suitable
western blot: suitable

isotype

IgG1

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

human ... CDKN2A(1029)

Specificity

P16* is a major tumor suppressor gene, which is known to be deleted or mutated in many types of human cancers. Antibody MAB4133 binds specifically to p16 in its recombinant or native form. It also recognizes p16 expressed by melanomas and neve in situ.

Immunogen

Recombinant p16 fusion protein from E. coli.

Application

Anti-p16 Antibody, clone D25 is a Mouse Monoclonal Antibody for detection of p16 also known as INK4a, MTS1, CDK4IN, CDKN2 & has been validated in WB & IHC.
Immunoblotting

Immunohistochemistry

Optimal working dilutions must be determined by end user.
Research Category
Epigenetics & Nuclear Function
Research Sub Category
Cell Cycle, DNA Replication & Repair

Linkage

Replaces: 04-239

Physical form

Format: Purified
Liquid in phosphate buffer, containing azide as a preservative.

Storage and Stability

Maintain refrigerated at 2-8°C in undiluted aliquots for up to 12 months.

Analysis Note

Control
POSITIVE CONTROL: HeLa cells

colon carcinoma

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Qi Song et al.
Nature communications, 13(1), 4167-4167 (2022-07-20)
Squamous cell carcinoma (SCC) and adenocarcinoma (AC) are two main histological subtypes of solid cancer; however, SCCs are derived from different organs with similar morphologies, and it is challenging to distinguish the origin of metastatic SCCs. Here we report a
C Grønhøj Larsen et al.
British journal of cancer, 110(6), 1587-1594 (2014-02-13)
A significant proportion of squamous cell carcinomas of the oropharynx (OP-SCC) are related to human papillomavirus (HPV) infection and p16 overexpression. This subgroup proves better prognosis and survival but no evidence exists on the correlation between HPV and p16 overexpression
Matt Lechner et al.
Oral oncology, 83, 32-37 (2018-08-14)
p16INK4A (p16) is the most widely used clinical biomarker for Human Papillomavirus (HPV) in head and neck squamous cell cancer (HNSCC). HPV is a favourable prognostic marker in HNSCC and is used for patient stratification. While p16 is a relatively
Alhadi Almangush et al.
British journal of cancer, 117(6), 856-866 (2017-07-29)
Identifying informative prognostic biomarkers for oral tongue squamous cell carcinoma (OTSCC) is of great importance in order to better predict tumour behaviour and to guide treatment planning. Here, we summarise existing evidence regarding immunohistochemical prognostic biomarkers for OTSCC. A systematic
Amelia B Thompson et al.
Journal of lower genital tract disease, 22(4), 340-347 (2018-09-01)
Anal cancer rates are increasing among HIV-infected persons. Although an efficacious human papillomavirus (HPV) vaccine is available, HPV vaccination rates remain low. Therefore, providers perform anal cancer screening, but there is no consensus on the optimal methods or timing of

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service